MX2015016058A - Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos. - Google Patents

Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos.

Info

Publication number
MX2015016058A
MX2015016058A MX2015016058A MX2015016058A MX2015016058A MX 2015016058 A MX2015016058 A MX 2015016058A MX 2015016058 A MX2015016058 A MX 2015016058A MX 2015016058 A MX2015016058 A MX 2015016058A MX 2015016058 A MX2015016058 A MX 2015016058A
Authority
MX
Mexico
Prior art keywords
systems
active agents
methods
compositions
respiratory delivery
Prior art date
Application number
MX2015016058A
Other languages
English (en)
Inventor
Lechuga-Ballesteros David
B Joshi Vidya
Reisner Colin
Fitzgerald Darken Patrick
Kumar Dwivedi Sarvajna
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of MX2015016058A publication Critical patent/MX2015016058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones farmacéuticas, sistemas y métodos adecuados para el suministro por vía respiratoria de una combinación fija de los agentes activos LAMA, LABA e ICS. Las composiciones farmacéuticas descritas en el presente documento pueden formularse para el suministro por vía respiratoria a través de un inhalador de dosis medida (MDI). También se describen en el presente documento sistemas de MDI para la administración de una combinación fija de los agentes activos LAMA, LABA e ICS, así como también se describen métodos para preparar y usar las composiciones y los sistemas descritos en el presente documento.
MX2015016058A 2013-05-22 2014-05-22 Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos. MX2015016058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361826424P 2013-05-22 2013-05-22
PCT/US2014/039234 WO2014190204A1 (en) 2013-05-22 2014-05-22 Compositions, methods & systems for respiratory delivery of three or more active agents

Publications (1)

Publication Number Publication Date
MX2015016058A true MX2015016058A (es) 2016-12-20

Family

ID=50942948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016058A MX2015016058A (es) 2013-05-22 2014-05-22 Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos.

Country Status (20)

Country Link
US (1) US20150150787A1 (es)
EP (1) EP2999460A1 (es)
JP (1) JP2016519160A (es)
KR (1) KR20160013134A (es)
CN (1) CN105392471A (es)
AU (1) AU2014268482A1 (es)
BR (1) BR112015028964A2 (es)
CA (1) CA2912927A1 (es)
CL (1) CL2015003422A1 (es)
CR (1) CR20150645A (es)
DO (1) DOP2015000284A (es)
HK (2) HK1221654A1 (es)
MX (1) MX2015016058A (es)
NI (1) NI201500163A (es)
PE (1) PE20160155A1 (es)
PH (1) PH12015502593A1 (es)
RU (1) RU2015154720A (es)
SG (1) SG11201509543YA (es)
WO (1) WO2014190204A1 (es)
ZA (1) ZA201509016B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2435024T3 (en) 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
KR101763625B1 (ko) * 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
AU2014352793B2 (en) * 2013-11-22 2019-05-09 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
MX2017003080A (es) 2014-09-09 2017-11-15 Vectura Ltd Formulacion que comprende glicopirrolato, metodo y aparato.
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2020123057A2 (en) * 2018-10-31 2020-06-18 Repurposed Therapeutics, Inc. Dba Defender Treatment of exposure to chlorine gas with scopolamine
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN111617138A (zh) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用
TW202317080A (zh) * 2021-07-09 2023-05-01 美商阿斯特捷利康有限責任公司 用於氣溶膠遞送之組合物、方法及系統
WO2023119093A1 (en) * 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
JP3708553B2 (ja) 1995-04-14 2005-10-19 ネクター セラピューティクス 向上した分散性を有する粉末型薬理組成物
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
ATE461692T1 (de) 1999-10-29 2010-04-15 Novartis Ag Trockenpulverzusammensetzungen mit verbesserter dispersität
AU2004251623B2 (en) 2003-05-28 2010-03-18 Novartis Ag Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
US8475845B2 (en) 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
DK2435024T3 (en) * 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2675439A2 (en) * 2011-02-17 2013-12-25 Cipla Limited Combination of glycopyrrolate and a beta2 -agonist
SG194896A1 (en) * 2011-05-17 2013-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents

Also Published As

Publication number Publication date
CN105392471A (zh) 2016-03-09
US20150150787A1 (en) 2015-06-04
SG11201509543YA (en) 2015-12-30
KR20160013134A (ko) 2016-02-03
JP2016519160A (ja) 2016-06-30
PE20160155A1 (es) 2016-04-01
CL2015003422A1 (es) 2016-09-02
AU2014268482A1 (en) 2016-01-07
PH12015502593A1 (en) 2016-02-29
RU2015154720A (ru) 2017-06-27
HK1221653A1 (zh) 2017-06-09
EP2999460A1 (en) 2016-03-30
ZA201509016B (en) 2018-07-25
NI201500163A (es) 2016-01-06
CR20150645A (es) 2016-02-10
CA2912927A1 (en) 2014-11-27
WO2014190204A1 (en) 2014-11-27
DOP2015000284A (es) 2016-04-29
BR112015028964A2 (pt) 2017-07-25
HK1221654A1 (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
AU2017265042B2 (en) Cannula for Minimizing Dilution of Dosing during Nitric Oxide Delivery
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
PH12015501096A1 (en) Composition for immediate and extended release
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
GB201209587D0 (en) Therapeutic compounds
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
MX2021009377A (es) Formulaciones de espuma y aparatos para su suministro.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.
RU2011145777A (ru) Лекарственное средство, обладающее ранозаживляющей, противовоспалительной активностью